2022
DOI: 10.1001/jamapsychiatry.2022.1142
|View full text |Cite
|
Sign up to set email alerts
|

The Course of General Cognitive Ability in Individuals With Psychotic Disorders

Abstract: IMPORTANCE Schizophrenia is associated with major cognitive deficits and has been conceptualized as both a neurodevelopmental and a neurodegenerative disorder. However, when deficits develop and how they change over the course of illness is uncertain.OBJECTIVE To trace cognition from elementary school to old age to test neurodevelopmental and neurodegenerative theories of psychotic disorders.DESIGN, SETTING, AND PARTICIPANTS Data were taken from the Suffolk County Mental Health Project, a first-admission longi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
24
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 42 publications
(32 citation statements)
references
References 62 publications
1
24
1
Order By: Relevance
“…Indeed, there is evidence that cognitive decline in psychosis starts at least a decade before the onset of psychotic symptoms, and this is more profound in individuals with schizophrenia, who experience a decrease in IQ at a rate of 0.35 points per year. 26 Additionally, a second acceleration of cognitive decline approximately two decades after disease onset, with an IQ decrease of 0.59 points per year, has also been reported. 26 Based on the cross-sectional design of the present study, the opposite may also be suggested, i.e.…”
Section: Discussionmentioning
confidence: 95%
See 1 more Smart Citation
“…Indeed, there is evidence that cognitive decline in psychosis starts at least a decade before the onset of psychotic symptoms, and this is more profound in individuals with schizophrenia, who experience a decrease in IQ at a rate of 0.35 points per year. 26 Additionally, a second acceleration of cognitive decline approximately two decades after disease onset, with an IQ decrease of 0.59 points per year, has also been reported. 26 Based on the cross-sectional design of the present study, the opposite may also be suggested, i.e.…”
Section: Discussionmentioning
confidence: 95%
“…26 Additionally, a second acceleration of cognitive decline approximately two decades after disease onset, with an IQ decrease of 0.59 points per year, has also been reported. 26 Based on the cross-sectional design of the present study, the opposite may also be suggested, i.e. that exposure to high doses of Variables excluded from the model: financial reimbursement, vocational status, gender, race, ethnicity, religion, family status, spoken language, mental health history, history of involuntary hospital admission, substance use history, family history of psychiatric disorders, dual diagnosis, high-dose antipsychotics (with 'as needed' medication regimens included), polypharmacy (with/without antipsychotics), psychiatric diagnosis, main symptoms leading to hospital admission, health-related behaviours before the admission, PANSS total score, negative symptoms PANSS subscale score, positive symptoms PANSS subscale score, relapse frequency.…”
Section: Discussionmentioning
confidence: 95%
“…Importantly, this measure is unlikely to be confounded with illness chronicity, as most education is completed prior to the onset of psychosis in individuals with SZ. Therefore, educational attainment is a reasonable index for premorbid cognitive deficits in individuals later diagnosed with SZ …”
Section: Discussionmentioning
confidence: 99%
“…The cognitive impairment associated with schizophrenia (CIAS) is remarkably robust, associated with the initial, prodromal stages of schizophrenia and closely linked to functional outcomes and quality of life [ 2 , 3 , 4 , 5 , 6 , 7 ]. A recent cohort study revealed that the start of cognitive decline precedes psychosis onset by over a decade, implying that cognitive deficits represent the underlying pathophysiology of schizophrenia, with psychosis being a secondary symptom [ 8 ]. Existing typical and atypical antipsychotic medications modifying monoamine receptors have shown value in mitigating the positive, but neither negative nor cognitive, symptoms [ 9 ].…”
Section: Introductionmentioning
confidence: 99%